Literature DB >> 19430461

Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures.

Zheng Zhou1, Juan Zhen, Nathan K Karpowich, Christopher J Law, Maarten E A Reith, Da-Neng Wang.   

Abstract

Sertraline and fluoxetine are selective serotonin re-uptake inhibitors (SSRIs) that are widely prescribed to treat depression. They exert their effects by inhibiting the presynaptic plasma membrane serotonin transporter (SERT). All SSRIs possess halogen atoms at specific positions, which are key determinants for the drugs' specificity for SERT. For the SERT protein, however, the structural basis of its specificity for SSRIs is poorly understood. Here we report the crystal structures of LeuT, a bacterial SERT homolog, in complex with sertraline, R-fluoxetine or S-fluoxetine. The SSRI halogens all bind to exactly the same pocket within LeuT. Mutation at this halogen-binding pocket (HBP) in SERT markedly reduces the transporter's affinity for SSRIs but not for tricyclic antidepressants. Conversely, when the only nonconserved HBP residue in both norepinephrine and dopamine transporters is mutated into that found in SERT, their affinities for all the three SSRIs increase uniformly. Thus, the specificity of SERT for SSRIs is dependent largely on interaction of the drug halogens with the protein's HBP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430461      PMCID: PMC2758934          DOI: 10.1038/nsmb.1602

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  43 in total

1.  Identification of a chloride ion binding site in Na+/Cl -dependent transporters.

Authors:  Lucy R Forrest; Sotiria Tavoulari; Yuan-Wei Zhang; Gary Rudnick; Barry Honig
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

2.  The mechanism of a neurotransmitter:sodium symporter--inward release of Na+ and substrate is triggered by substrate in a second binding site.

Authors:  Lei Shi; Matthias Quick; Yongfang Zhao; Harel Weinstein; Jonathan A Javitch
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

3.  Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter.

Authors:  E L Barker; R D Blakely
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

Review 4.  Neurotransmitter transporters and their impact on the development of psychopharmacology.

Authors:  Leslie Iversen
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.

Authors:  Thorsten Lehr; Alexander Staab; Christiane Tillmann; Dirk Trommeshauser; Andreas Raschig; Hans Guenter Schaefer; Charlotte Kloft
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

6.  Structure and localisation of drug binding sites on neurotransmitter transporters.

Authors:  Aina W Ravna; Ingebrigt Sylte; Svein G Dahl
Journal:  J Mol Model       Date:  2009-02-24       Impact factor: 1.810

7.  Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding.

Authors:  Nianhang Chen; Judy Rickey; Janet L Berfield; Maarten E A Reith
Journal:  J Biol Chem       Date:  2003-12-02       Impact factor: 5.157

8.  Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition.

Authors:  Crystal C Walline; David E Nichols; F Ivy Carroll; Eric L Barker
Journal:  J Pharmacol Exp Ther       Date:  2008-03-19       Impact factor: 4.030

9.  Mechanism of chloride interaction with neurotransmitter:sodium symporters.

Authors:  Elia Zomot; Annie Bendahan; Matthias Quick; Yongfang Zhao; Jonathan A Javitch; Baruch I Kanner
Journal:  Nature       Date:  2007-08-19       Impact factor: 49.962

10.  Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.

Authors:  Satinder K Singh; Atsuko Yamashita; Eric Gouaux
Journal:  Nature       Date:  2007-08-08       Impact factor: 49.962

View more
  116 in total

1.  The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast.

Authors:  Meredith M Rainey; Daniel Korostyshevsky; Sean Lee; Ethan O Perlstein
Journal:  Genetics       Date:  2010-05-10       Impact factor: 4.562

2.  Identification of a second substrate-binding site in solute-sodium symporters.

Authors:  Zheng Li; Ashley S E Lee; Susanne Bracher; Heinrich Jung; Aviv Paz; Jay P Kumar; Jeff Abramson; Matthias Quick; Lei Shi
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

3.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

4.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

Review 5.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

6.  Insights into transport mechanism from LeuT engineered to transport tryptophan.

Authors:  Chayne L Piscitelli; Eric Gouaux
Journal:  EMBO J       Date:  2011-09-27       Impact factor: 11.598

Review 7.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

8.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

9.  Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.

Authors:  Sankar Manepalli; Laura M Geffert; Christopher K Surratt; Jeffry D Madura
Journal:  J Chem Inf Model       Date:  2011-09-02       Impact factor: 4.956

Review 10.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.